1	Incidence, symptoms and medical care for influenza virus and respiratory syncytial
2	virus illnesses among older adults in Eastern China: Findings from the China Ageing
3	Respiratory Infections Study (CARES), 2015-2017
4	
5	Table of Contents
6	Additional information on Methods2
7	Monitoring for acute respiratory illness (ARI)2
8	Primary outcomes and statistical analyses3
9	Additional information on Results6
10	Active surveillance for acute respiratory illness (ARI)6
11	Appendix Tables7
12	Appendix Figures
13	References23
14	
15	

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Additional information on Methods

Monitoring for acute respiratory illness (ARI)

We conducted active surveillance for acute respiratory illness (ARI) throughout the year (December 2015-September 2017) with weekly telephone calls because influenza viruses are known to circulate outside of the typical winter season in eastern China, though we expected RSV to circulate mostly in winter seasons. 1,2 To monitor for ARI, we contacted participants every week by telephone until the participants or their proxies were successfully reached. Follow-up with a proxy was used if the participant did not have a phone or was unreachable at the time that weekly calls were conducted. To allow assessment of the quality of reporting by beginning in May 2016, we recorded whether the participant or a proxy was reached during the weekly follow-up calls for illness. If the study participant was not present during the weekly follow-up call and a proxy answered questions about participant illness, the proxy was asked if they interacted with the participant daily since the last follow-up call. During the weekly calls, we asked if the participant was experiencing a new onset of an acute illness by asking about respiratory symptoms. If fever was reported, the participant was asked whether it was subjective feverishness, chills, or measured temperature ≥37⋅8°C and the participant was asked about other symptoms being experienced. Illness episodes with onset dates that were ≥14 days apart were considered separate illness episodes. If an ARI episode was identified, a home visit was arranged to collect respiratory swab specimens (combined midturbinate and oropharyngeal swab) within 7 days of symptom onset for laboratory confirmation of influenza virus and RSV infections. During the household visit, study staff completed an acute illness episode questionnaire that recorded illness symptoms (such as cough, sore throat, congestion, self-reported fever or measured temperature) and duration, clinical characteristics, self-reported health and functioning, cognitive functioning, and whether medical care was sought. Participants described subjective severity of each symptom

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

as absent, mild, moderate, or severe (0-3, respectively),^{3,4} and mean symptom severity score (1-3) was calculated for those meeting the ARI definition. Participants reported their overall health on the day of the acute illness survey using a visual analogue thermometer (from 0 [worst health state you can imagine] to 100 [best health state you can imagine]).⁵ During the same survey, participants rated their ability to complete their regular activities from 0% (unable to do any activities and responsibilities) to 100% (able to do all activities and responsibilities). Cognitive functioning was assessed with short-term recall of three words.^{6,7} About 10 days after illness onset, a follow-up questionnaire was completed by telephone to obtain information about illness resolution and outcome. Participants were asked if they had recovered at 10 days after illness onset; if not, they were contacted every three days by telephone until the illness resolved or there was confirmation of patient death. Additionally, participants also reported whether or not they received medical care during their illness (including hospitalization), the use of antibiotics or over-the-counter medications, and the number days spent in bed for at least half of the day.8 Data were captured and stored in a real-time online database, REDCap (Research Electronic Data Capture). Weekly data checks were completed to ensure that all participants were contacted weekly. Respiratory specimens were placed in coolers at 2–8°C and transported to the Suzhou Center for Disease Prevention and Control (CDC) or Yancheng CDC laboratories within 24 hours of collection. Aliquots of specimens were stored at -80°C until testing was completed.⁷ Primary outcomes and statistical analyses We defined the cumulative incidence of influenza or RSV ARIs as the proportion of participants with PCR-confirmed influenza virus or RSV infections among participants

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

enrolled at the start of each study year. Study Year 1 was 27 December 2015–3 September 2016 and Year 2 was 4 September 2016–2 September 2017. Based on previous studies, we anticipated a cumulative incidence of influenza ARI of 2–4% in older adults per year. ^{10,11} To estimate a cumulative incidence of influenza ARI of 2% with ±0.7% margin of error, we aimed to enroll a sample size of 1,500 older adults. We also estimated the weekly incidence rates of influenza or RSV viruses from symptom onset date per 10,000 person-weeks of follow-up, defining each week from Sunday through Saturday. Participants were included in person-week count if they were contacted and responded to follow-up questions in that week. 12 We estimated the cumulative and weekly incidence by age group and calculated allage estimates, using the Jiangsu Province population to weight by age and sex (Appendix Figure 1). We estimated 95% confidence intervals (95% CIs) for the cumulative and weekly incidence using a bootstrap with 2,000 resamples. 13,14 If there were no illness outcomes observed (e.g., ARI, ILI, influenza or RSV) during a surveillance week, the incidence point estimate was zero and uncertainty regarding the true incidence was represented as (0, 3/n) where n was the number of participants followed. 14 Clinical characteristics, illness duration, cognitive functioning, self-reported health and functioning, and medical care for ARI episodes were captured during illness interviews. Participants described subjective severity of each symptom as absent, mild, moderate, or severe and responses were scored as 0–3, respectively for each severity level.^{3,4} We classified symptoms into categories: upper respiratory symptoms (sore throat, runny nose or nasal congestion), lower respiratory symptoms (cough, shortness of breath), and systemic symptoms (myalgias, headache, and self-reported fever including feverishness, chills, or measured fever ≥ 37.8 °C). ¹⁵ We constructed symptom severity scores for each category by adding self-reported symptom scores ranging from 0-3 depending on severity level and

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

dividing by the number of symptoms in the symptom category. The constructed symptom category severity scores ranged from 0-3. Illness duration was defined as the number of days experiencing any ARI symptoms. Illness days in bed was calculated as the number days spent in bed for at least half of the day.8 During illness, cognitive functioning was assessed with short-term recall of three words, ^{6,7} self-rated (overall) health state with a visual analogue thermometer (from 0 [worst health state you can imagine] to 100 [best health state you can imagine]),⁵ and whether participants were able to complete their regular activities from 0% (unable to do any of your activities and responsibilities) to 100% (able to do all your activities and responsibilities). Participants also self-reported whether or not they received medical care during their illness, medication use (e.g., antipyretics, antibiotics, and antiviral medications), and if they were hospitalized (including duration of hospitalization). If participant death was reported, causes of death were obtained through medical records, death certificates, or family members. We compared illness characteristics of ARI episodes with PCR-confirmed influenza ('influenza ARI') or ARI episodes with PCR-confirmed RSV infections ('RSV ARI'), with ARI episodes that were influenza and RSV PCR-negative ('influenza and RSV PCR-negative ARI'): we used Student's t test for comparison of severity scores and illness duration variables, and Fisher's exact test for comparison of cognitive functioning, symptoms and medical care. Analyses were done using R version 4.2.2 (R Foundation for Statistical Computing, Vienna,

109

110

111

Analyses were done using R version 4.2.2 (R Foundation for Statistical Computing, Vienna, Austria), with the geospatial data obtained from the Global Administrative Areas (GADM) database version 2.8.16

113

Additional information on Results

Active surveillance for acute respiratory illness (ARI)

During active surveillance for ARI, January 2016—August 2017, we contacted participants every week and either spoke to the individual or a proxy to assess new onset of symptoms since our last contact. One thousand five hundred and two participants translated to a possible 124,091 weeks eligible for active surveillance. In May 2016, we began to record if health status was reported by the participant or a proxy. Of 97,914 successful weekly contacts, 69,911 (71%) reached the participant directly and 26,531 (27%) reached a proxy to access health status. When a proxy was reached, they were asked if they had regular contact with the participant. Nearly all proxy contacts (26,363, 99%) reported meeting the participant daily. Using these weekly contacts, we assessed health status for 120,484/124,091 (97%) personweeks of follow-up. We identified 1,043 reports of acute illness. Of those, 898 (86%) episodes reported by 522 participants met the ARI definition.

128 **Appendix Tables**

129 Appendix Table 1. Definition of illness definitions and outcomes and self-reported health status.

Outcome	Definition/ Measurement	Reference
Illness		
Acute respiratory illness	Sudden onset of two or more of the following symptoms in the past 7	
(ARI)	days: fever (self-reported feverishness, chills, or temperature ≥	
	37-8°C), cough, sore throat, runny nose or nasal congestion,	
	headache, myalgia (body or muscle aches and pain), or worsened shortness of breath.	
Influenza-like illness (ILI)	An ARI with measured fever of $\geq 37.8^{\circ}$ C (self-reported and/or measured by study staff) plus cough.	
Medically-attended ARI	An ARI with a self-reported medical visit to a doctor or other medical professional during the acute illness, including visits to outpatient medical clinic/offices, emergency rooms, or hospitals.	
ARI-associated	A self-reported hospitalization (i.e. staying in the hospital for at least	
hospitalization	one night as a patient) during an ARI.	
ARI-associated death	A death that occurs within 14 days of ARI symptom onset.	
<u>Health status</u>		
Number of days in bed	Number of days the participant stayed in bed for at least half the day while he/ she was sick.	Searle SD et al, BMC Geriatr 2008; 8:24.
Cognitive function	Two measures were used: (1) A 3-item recall in the Mini-Cog tool, i.e. the number of words recalled after a several-minute delay and distraction. (2) The full Standardised Mini-Mental State Examination (SMMSE).	Borson S et al, Int J Geriatr Psychiatry 2000; 15:1021-7; Molloy DW et al, Am J Psychiatry 1991; 148:102-5.
Self-rate health state	A visual analogue scale (VAS) adapted from the EQ-5D with a range from 0 to 100, where the participant self-evaluated how he/she is feeling today, with the best health state he/she can imagine as 100 at the top, and the worst health state he/she can imagine as 0 at the bottom.	Wu C et al, PLoS One 2016; 11:e0164334.
Self-rated activity level	Participant was asked to self-evaluate how his/ her illness has affected his/her life and activities with a range from 0 to 100, where 100% means he/ she was able to do all his/ her activities and responsibilities as he/ she would normally, and 0% means he/ she was unable to do any of his/ her activities or responsibilities.	

131 Appendix Table 2. Reasons for participant withdrawal or loss to follow-up.

Cause of withdrawal	Number of participants (N = 190)
Death	84 (44%)
Cancer	30 (16%)
Stroke	17 (9%)
Cardiovascular disease	17 (9%)
Chronic lung disease	4 (2%)
Neurologic disorder (e.g. Alzheimer's disease)	3 (2%)
Accident	3 (2%)
Diabetes	2 (1%)
Others	8 (4%)
No longer interested in participating	81 (43%)
Relocated	14 (7%)
Deteriorate health	7 (4%)
Lost contact	2 (1%)
Others	2 (1%)

133 134 Appendix Table 3. Proportion of participants with acute respiratory illness (ARI), medically attended ARI, ARI-associated hospitalization and death by age group in New District, Suzhou.

				Age (years)				
		Ye	ar 1			Year 2			
		Age	(years)		Age (years)				
	60 – 69	70 – 79	80 – 89	Total	60 – 69	70 – 79	80 – 89	Total	
Number of person-week with follow-up attempt	4423	4577	3753	12753	6360	6454	5128	17942	
Number of person-week with successful follow up $(n, \%)$	4238 (95.8)	4356 (95.2)	3572 (95.2)	12166 (95.4)	6176 (97.1)	6233 (96.6)	4976 (97)	17385 (96.9)	
	No	o. of part	icipants	(%)	No	o. of part	icipants	(%)	
	(N=126)	(N=135)	(N=113)	(N=374)	(N=124)	(N=130)	(N=107)	(N=361)	
Participants followed ¹									
Number of participants at start of year	126	135	113	374	124	130	107	361	
Acute respiratory illness and medical care									
Acute respiratory illness (ARI)									
Participants with one ARI episode only	12 (10)	20 (15)	15 (13)	47 (13)	21 (17)	19 (15)	20 (19)	60 (17)	
Participants with two or more ARI episodes	5 (4)	1(1)	3 (3)	9 (2)	2 (2)	4 (3)	3 (3)	9 (2)	
Participants with one influenza ARI episode only	0 (0)	0 (0)	2 (1.8)	2 (0.5)	3 (2.4)	6 (4.6)	3 (2.8)	12 (3.3)	
Participants with two or more influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Participants with one RSV ARI episode only	0 (0)	2 (1.5)	0 (0)	2 (0.5)	1 (0.8)	0 (0)	2 (1.9)	3 (0.8)	
Medically attended ARI ²									
Participants with one medically attended ARI episode only	5 (4)	6 (4)	12 (11)	23 (6)	13 (10)	13 (10)	11 (10)	37 (10)	
Participants with two or more medically attended ARI episodes	2 (2)	0 (0)	0 (0)	2(1)	0 (0)	1(1)	2 (2)	3 (1)	
Participants with one medically attended influenza ARI episode only	0 (0)	0 (0)	1 (0.9)	1 (0.3)	2 (1.6)	4 (3.1)	2 (1.9)	8 (2.2)	
Participants with two or more medically attended influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Participants with one medically attended RSV ARI episode only	0 (0)	1 (0.7)	0 (0)	1 (0.3)	1 (0.8)	0 (0)	2 (1.9)	3 (0.8)	
ARI-associated hospitalization ³									
Participants with one hospitalization only	0 (0)	0 (0)	3 (2.7)	3 (0.8)	0 (0)	0(0)	3 (2.8)	3 (0.8)	
Participants with one hospitalization with influenza ARI only	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Participants with one hospitalization with RSV ARI only	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0(0)	0 (0)	
Death within 14 days of ARI symptom onset ⁴									
Deaths	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Deaths with influenza	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Deaths with RSV	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	

¹ All participants were enrolled at the start of the study with no replenishment. Year 1: 27 December 2015 – 3 September 2016; Year 2: 4 September 2016 – 2 September 2017.

2 A medically attended ARI episode is defined as an ARI with a self-reported medical visit to a doctor or other medical professional for this

illness including outpatient medical clinic/offices, emergency rooms or was hospitalized, reported during the acute illness.

3 An ARI-associated hospitalization is defined as an ARI with a self-reported hospitalization, reported during the acute illness.

4 One death during ARI with PCR-confirmed RSV infection but this case was not hospitalized.

143 144 Appendix Table 4. Proportion of participants with acute respiratory illness (ARI), medically attended ARI, ARI-associated hospitalization, and death by age group in Xiangcheng, Suzhou.

				Age (years)				
		Ye	ar 1			Year 2			
	Age (years)			Age (years)					
	60 - 69	70 – 79	80 – 89	Total	60 – 69	70 – 79	80 – 89	Total	
Number of person-week with follow-up attempt	5582	4465	3391	13438	7364	6210	4449	18023	
Number of person-week with successful follow up (n, $\%$)	5264 (94.3)	4087 (91.5)	2956 (87.2)	12307 (91.6)	7164 (97.3)	6051 (97.4)	4300 (96.7)	17515 (97.2)	
	No	o. of part	ticipants	(%)	N	o. of par	ticipants	(%)	
	(N=126)	(N=135)	(N=113)	(N=374)	(N=124)	(N=130)	(N=107)	(N=361)	
Participants followed ¹									
Number of participants at start of year	167	127	100	394	152	125	93	370	
Acute respiratory illness and medical care									
Acute respiratory illness (ARI)									
Participants with one ARI episode only	33 (20)	23 (18)	13 (13)	69 (18)	26 (17)	39 (31)	16 (17)	81 (22)	
Participants with two or more ARI episodes	14 (8)	9 (7)	2(2)	25 (6)	21 (14)	20 (16)	12 (13)	53 (14)	
Participants with one influenza ARI episode only	4 (2.4)	2 (1.6)	0 (0)	6 (1.5)	13 (8.6)	8 (6.4)	5 (5.4)	26 (7)	
Participants with two or more influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.8)	0 (0)	1 (0.3)	
Participants with one RSV ARI episode only	1 (0.6)	1 (0.8)	0 (0)	2 (0.5)	1 (0.7)	3 (2.4)	2 (2.2)	6 (1.6)	
Medically attended ARI ²									
Participants with one medically attended ARI episode only	25 (15)	14 (11)	9 (9)	48 (12)	17 (11)	23 (18)	11 (12)	51 (14)	
Participants with two or more medically attended ARI episodes	3 (2)	1(1)	1 (1)	5 (1)	13 (9)	8 (6)	4 (4)	25 (7)	
Participants with one medically attended influenza ARI episode only	4 (2.4)	1 (0.8)	0 (0)	5 (1.3)	11 (7.2)	5 (4)	1 (1.1)	17 (4.6)	
Participants with two or more medically attended influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.8)	0 (0)	1 (0.3)	
Participants with one medically attended RSV ARI episode only	1 (0.6)	0 (0)	0 (0)	1 (0.3)	0 (0)	2 (1.6)	0 (0)	2 (0.5)	
ARI-associated hospitalization ³									
Participants with one hospitalization only	1 (0.6)	1 (0.8)	2 (2)	4(1)	1 (0.7)	4 (3.2)	3 (3.2)	8 (2.2)	
Participants with one hospitalization with influenza ARI only	1 (0.6)	0(0)	0 (0)	1 (0.3)	1 (0.7)	0(0)	0 (0)	1 (0.3)	
Participants with one hospitalization with RSV ARI only	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	1 (0.8)	0 (0)	1 (0.3)	
Death within 14 days of ARI symptom onset ⁴									
Deaths	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Deaths with influenza	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Deaths with RSV	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0(0)	

¹ All participants were enrolled at the start of the study with no replenishment. Year 1: 27 December 2015 – 3 September 2016; Year 2: 4

September 2016 – 2 September 2017.

2 A medically attended ARI episode is defined as an ARI with a self-reported medical visit to a doctor or other medical professional for this illness including outpatient medical clinic/offices, emergency rooms or was hospitalized, reported during the acute illness.

3 An ARI-associated hospitalization is defined as an ARI with a self-reported hospitalization, reported during the acute illness.

4 One death during ARI with PCR-confirmed RSV infection but this case was not hospitalized.

Appendix Table 5. Proportion of participants with acute respiratory illness (ARI), medically attended ARI, ARI-associated hospitalization, and death by age group in Economic Development Zone (EDZ), Yancheng.

				Age (years)				
		Ye	ear 1			Year 2			
	Age (years)				Age (years)				
	60 – 69	70 – 79	80 – 89	Total	60 – 69	70 – 79	80 – 89	Total	
Number of person-week with follow-up attempt	2798	2772	2763	8333	4032	3923	4019	11974	
Number of person-week with successful follow up (n, %)	2710	2683	2680	8073	4030	3917	4016	11963	
• • • • • • • • • • • • • • • • • • • •	(96.9)	(96.8)	(97)	(96.9)	(100)	(99.8)	(99.9)	(99.9)	
	No	o. of part	ticipants	(%)	No	o. of part	ticipants	(%)	
	(N=126)	(N=135)	(N=113)	(N=374)	(N=124)	(N=130)	(N=107)	(N=361)	
Participants followed ¹									
Number of participants at start of year	88	85	84	257	82	79	81	242	
Acute respiratory illness and medical care									
Acute respiratory illness (ARI)									
Participants with one ARI episode only	10 (11)	11 (13)	5 (6)	26 (10)	12 (15)	23 (29)	19 (23)	54 (22)	
Participants with two or more ARI episodes	4 (5)	4 (5)	2(2)	10 (4)	8 (10)	10 (13)	7 (9)	25 (10)	
Participants with one influenza ARI episode only	0 (0)	0 (0)	0 (0)	0 (0)	4 (4.9)	9 (11.4)	8 (9.9)	21 (8.7)	
Participants with two or more influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Participants with one RSV ARI episode only	1 (1.1)	0 (0)	0 (0)	1 (0.4)	2 (2.4)	0 (0)	1 (1.2)	3 (1.2)	
Medically attended ARI ²									
Participants with one medically attended ARI episode only	7 (8)	8 (9)	4 (5)	19 (7)	13 (16)	22 (28)	17 (21)	52 (21)	
Participants with two or more medically attended ARI episodes	2 (2)	2 (2)	2 (2)	6 (2)	3 (4)	5 (6)	4 (5)	12 (5)	
Participants with one medically attended influenza ARI episode only	0 (0)	0 (0)	0 (0)	0 (0)	4 (4.9)	9 (11.4)	7 (8.6)	20 (8.3)	
Participants with two or more medically attended influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Participants with one medically attended RSV ARI episode only	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.2)	0 (0)	1 (1.2)	2 (0.8)	
ARI-associated hospitalization ³									
Participants with one hospitalization only	0 (0)	2 (2.4)	0 (0)	2 (0.8)	1 (1.2)	0 (0)	1 (1.2)	2 (0.8)	
Participants with one hospitalization with influenza ARI only	0 (0)	0 (0)	0 (0)	0 (0)	1 (1.2)	0 (0)	0 (0)	1 (0.4)	
Participants with one hospitalization with RSV ARI only	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Death within 14 days of ARI symptom onset ⁴									
Deaths	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Deaths with influenza	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	
Deaths with RSV	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	

¹ All participants were enrolled at the start of the study with no replenishment. Year 1: 27 December 2015 – 3 September 2016; Year 2: 4 September 2016 – 2 September 2017.

² Å medically attended ARI episode is defined as an ARI with a self-reported medical visit to a doctor or other medical professional for this illness including outpatient medical clinic/offices, emergency rooms or was hospitalized, reported during the acute illness.

³ An ARI-associated hospitalization is defined as an ARI with a self-reported hospitalization, reported during the acute illness. 4 One death during ARI with PCR-confirmed RSV infection but this case was not hospitalized.

Appendix Table 6. Proportion of participants with acute respiratory illness (ARI), medically attended ARI, ARI-associated hospitalization, and death by age group in Tinghu, Yancheng.

				Age (years)					
		Ye	ar 1			Year 2				
	Age (years)				Age (years)					
	60 - 69	70 – 79	80 – 89	Total	60 – 69	70 – 79	80 – 89	Total		
Number of person-week with follow-up attempt	5596	5611	5613	16820	8498	8278	8032	24808		
Number of person-week with successful follow up $(n, \%)$	5419 (96.8)	5423 (96.6)	5437 (96.9)	16279 (96.8)	8494 (100)	8272 (99.9)	8030 (100)	24796 (100)		
	No	o. of part	cicipants	(%)	No	o. of part	cicipants	(%)		
	(N=126)	(N=135)	(N=113)	(N=374)	(N=124)	(N=130)	(N=107)	(N=361)		
Participants followed ¹										
Number of participants at start of year	166	168	168	502	166	166	165	497		
Acute respiratory illness and medical care										
Acute respiratory illness (ARI)										
Participants with one ARI episode only	20 (12)	22 (13)	23 (14)	65 (13)	30 (18)	29 (17)	22 (13)	81 (16)		
Participants with two or more ARI episodes	8 (5)	7 (4)	2(1)	17 (3)	16 (10)	11 (7)	6 (4)	33 (7)		
Participants with one influenza ARI episode only	2 (1.2)	0 (0)	0 (0)	2 (0.4)	10 (6)	11 (6.6)	3 (1.8)	24 (4.8)		
Participants with two or more influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		
Participants with one RSV ARI episode only	1 (0.6)	0 (0)	1 (0.6)	2 (0.4)	1 (0.6)	2 (1.2)	0 (0)	3 (0.6)		
Medically attended ARI ²										
Participants with one medically attended ARI episode only	19 (11)	15 (9)	17 (10)	51 (10)	31 (19)	28 (17)	23 (14)	82 (16)		
Participants with two or more medically attended ARI episodes	6 (4)	7 (4)	1 (1)	14 (3)	15 (9)	11 (7)	4 (2)	30 (6)		
Participants with one medically attended influenza ARI episode only	2 (1.2)	0 (0)	0 (0)	2 (0.4)	10 (6)	11 (6.6)	2 (1.2)	23 (4.6)		
Participants with two or more medically attended influenza ARI episodes	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		
Participants with one medically attended RSV ARI episode only	1 (0.6)	0 (0)	0 (0)	1 (0.2)	1 (0.6)	1 (0.6)	0 (0)	2 (0.4)		
ARI-associated hospitalization ³										
Participants with one hospitalization only	0 (0)	0 (0)	0 (0)	0 (0)	2 (1.2)	1 (0.6)	1 (0.6)	4 (0.8)		
Participants with one hospitalization with influenza ARI only	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.6)	0 (0)	1 (0.2)		
Participants with one hospitalization with RSV ARI only	0 (0)	0(0)	0 (0)	0 (0)	0 (0)	0(0)	0 (0)	0 (0)		
Death within 14 days of ARI symptom onset ⁴										
Deaths	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.6)	0 (0)	1 (0.2)		
Deaths with influenza	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)		
Deaths with RSV	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (0.6)	0 (0)	1 (0.2)		

¹ All participants were enrolled at the start of the study with no replenishment. Year 1: 27 December 2015 – 3 September 2016; Year 2: 4

September 2016 – 2 September 2017.

2 A medically attended ARI episode is defined as an ARI with a self-reported medical visit to a doctor or other medical professional for this illness including outpatient medical clinic/offices, emergency rooms or was hospitalized, reported during the acute illness.

³ An ARI-associated hospitalization is defined as an ARI with a self-reported hospitalization, reported during the acute illness. 4 One death during ARI with PCR-confirmed RSV infection but this case was not hospitalized.

Appendix Table 7. Incidence rate of acute respiratory illness (ARI), influenza-like illness (ILI), PCR-confirmed influenza ARI, and PCR-confirmed RSV ARI per 10,000 person-years by age group.

	Incidence	Incidence rate per 10,000 person-years (%, 95% confidence interval)							
Age (years)	60 – 69	70 – 79	80 – 89	Overall (weighed) ⁶					
<u>Year 1</u> (27 December 2015 – 3 September 2	2016)								
Number of person-week with follow-up	40000	45.405	15500	71011					
attempt Number of person-week with successful	18399	17425	15520	51344					
follow up (n, %)	17631 (95.8%)	16549 (95.0%)	14645 (94.4%)	48825 (95·1%)					
Acute respiratory illness (ARI) ¹	4380 (3699, 5061)	3878 (3248, 4572)	2672 (2102, 3243)	3940 (3473, 4394)					
Influenza-like illness (ILI) ²	621 (385, 888)	536 (315, 788)	570 (321, 856)	590 (422, 789)					
PCR-confirmed influenza ARI									
All	178 (59, 355)	63 (0, 158)	71 (0, 178)	125 (49, 220)					
Medically attended ³	178 (59, 326)	32 (0, 95)	36 (0, 107)	111 (34, 212)					
Hospitalized ⁴	30 (0, 89)	0 (0, 95)	0 (0, 107)	15 (0, 44)					
PCR-confirmed RSV ARI									
All	89 (0, 207)	95 (0, 221)	36 (0, 107)	83 (26, 172)					
Medically attended	59 (0, 148)	32 (0, 95)	0 (0, 107)	42 (0, 116)					
Hospitalized ⁵	0 (0, 89)	0 (0, 95)	0 (0, 107)	0 (0, 32)					
Year 2 (4 September 2016 – 2 September 2	017)								
Number of person-week with follow-up	,								
attempt	26254	24865	21628	72747					
Number of person-week with successful follow up (n, %)	25864 (98.5%)	24473 (98·4%)	21322 (98.6%)	71659 (98.5%)					
Acute respiratory illness (ARI)	4095 (3551, 4660)	4499 (3902, 5117)	3402 (2838, 3940)	4204 (3806, 4640)					
Influenza-like illness (ILI)	605 (403, 827)	725 (490, 981)	514 (318, 783)	640 (492, 807)					
PCR-confirmed influenza ARI	, , ,	, ,	, , ,	` ' '					
All	605 (403, 827)	768 (533, 1023)	465 (269, 685)	648 (501, 821)					
Medically attended	545 (343, 746)	661 (426, 895)	294 (147, 465)	572 (429, 738)					
Hospitalized	40 (0, 101)	21 (0, 64)	0 (0, 73)	35 (0, 81)					
PCR-confirmed RSV ARI									
All	101 (20, 202)	107 (21, 213)	122 (24, 245)	101 (47, 165)					
Medically attended	61 (0, 141)	64 (0, 149)	73 (0, 171)	58 (21, 114)					
Hospitalized	0 (0, 61)	21 (0, 64)	0 (0, 73)	6 (0, 17)					

¹ Acute respiratory illness (ARI) is defined as an acute onset of ≥2 of the following symptoms in the past 7 days: fever (self-reported feverishness, chills, or temperature ≥37·8°C), cough, sore throat, runny nose or nasal congestion, headache, myalgia (body or muscle aches and pain), or worsened shortness of breath.

² Influenza-like illness (ILI) is defined as an ARI with measured fever of ≥37·8°C (self-reported and/or measured by study staff) plus cough.

³ Medically-attended ARI is defined as an ARI with a self-reported medical visit to a doctor or other medical professional during the acute illness, including visits to outpatient medical clinic/offices, emergency rooms, or hospitals.

⁴ ARI-associated hospitalization is defined as a self-reported hospitalization (i.e. staying in the hospital for at least one night as a patient) during an ARI.

⁵ There were no hospitalizations with PCR-confirmed RSV infections.

⁶ Weighed with Jiangsu province population age and sex structure.

Appendix Table 8. Self-reported symptoms and symptom severity score among all acute respiratory illness (ARI), PCR-negative ARI, PCR-confirmed influenza ARI, and PCR-confirmed RSV ARI.

		Acute respiratory illness (ARI) episodes									
	All ARI	ARI with PCR negative for both influenza and RSV	influenza		PCR-confirm		PCR- confirmed influenza vs. RSV ARI				
	(N=822)	(N=705)	(N=93	3)	(N=20))					
	n (%)	n (%)	n (%)	p-value ³	n (%)	p-value ⁴	p-value ⁵				
Symptoms											
Upper respiratory											
Sore throat	500 (61)	430 (61)	55 (59)	0.65	15 (75)	0.31	0.27				
Runny nose or nasal	738 (90)	636 (90)	80 (86)	0.27	18 (90)	>0.99	0.69				
congestion	730 (70)	020 (70)	00 (00)	0 27	10 (50)	, 0 , ,	0 0)				
Lower respiratory											
Cough	787 (96)	678 (96)	89 (96)	0.77	20 (100)	>0.99	>0.99				
Worsened shortness of breath	138 (17)	117 (17)	17 (18)	0.76	4 (20)	0.74	>0.99				
Systemic											
Fever	490 (60)	413 (59)	63 (68)	0.14	11 (55)	0.61	0.26				
Feverish	368 (45)	307 (44)	51 (55)	0.04	6 (30)	0.20	0.03				
Chills	317 (39)	266 (38)	43 (46)	0.13	7 (35)	0.80	0.41				
$Measured\ temperature \geq \\ 37{\cdot}8^{\circ}C$	147 (18)	119 (17)	23 (25)	0.04	3 (15)	>0.99	0.33				
Myalgia (Body or muscle	290 (35)	242 (34)	37 (40)	0.48	11 (55)	0.20	0.41				
aches and pain) Headache	500 (61)	428 (61)	55 (59)	0.82	14 (70)	0.31	0.28				
<u>Case definitions</u> Influenza-like illness (ILI) ¹ Illness with any		114 (16)	22 (24)	0.04	3 (15)	>0.99	0.49				
respiratory symptoms	819 (100)	703 (100)	93 (100)	>0.99	20 (100)	>0.99	-				
Illness with any upper respiratory symptoms	793 (96)	683 (97)	88 (95)	0.52	18 (90)	0.41	0.57				
Illness with any lower respiratory symptoms	790 (96)	680 (96)	89 (96)	0.56	20 (100)	>0.99	>0.99				
Illness with any systemic symptoms	686 (83)	585 (83)	80 (86)	0.65	17 (85)	0.74	0.71				
	Mean (95% CI)	Mean (95% CI)	Mean (95% CI) p-value ³	n (%)	p-value ⁴	p-value ⁵				
Symptom severity score	CI)	<u>C1)</u>									
Symptoms											
Sore throat	0.8 (0.7, 0.8)	0.8 (0.7, 0.8)	0.7(0.6, 0.8)	0.41	0.8(0.6, 1.1)	0.58	0.40				
Runny nose or nasal congestion	1.2 (1.2, 1.3)	1.2 (1.2, 1.3)	1.2 (1.1, 1.4)	0.87	1.3 (1.0, 1.6)	0.64	0.61				
Cough	1.4 (1.4, 1.5)	1.4 (1.3, 1.4)	1.5 (1.3, 1.6)	0.31	1.8 (1.4, 2.1)	0.06	0.15				
Worsened shortness of breath	0.2 (0.2, 0.2)	0.2 (0.2, 0.2)	0.2 (0.1, 0.4)	0.41	0.2 (0, 0.4)	0.96	0.62				
Feverishness	0.5 (0.5, 0.6)	0.5 (0.5, 0.6)	0.7 (0.6, 0.9)	0.02	0.4 (0.1, 0.7)	0.19	0.03				
Chills	0.5 (0.3, 0.0) 0.5 (0.4, 0.5)	0.4 (0.4, 0.5)	0.6 (0.4, 0.7)	0.14	0.4 (0.1, 0.7) 0.4 (0.2, 0.7)	0.19	0.29				
Myalgia (Body or muscle	0.4 (0.4, 0.5)	0.4 (0.4, 0.3)	0.5 (0.3, 0.6)	0.14	0.7 (0.4, 0.9)	0.04	0.29				
aches and pain) Headache	0.7 (0.7.0.9)	0.7 (0.7.0.9)	0.7 (0.6, 0.8)	0.87	0.9 (0.6, 1.2)	0.31	0.30				
Symptom categories ²	0.7 (0.7, 0.8)	0.7 (0.7, 0.8)	0.7 (0.0, 0.8)	0.97	0.3 (0.0, 1.2)	0.31	0.30				
	0.7 (0.7.0.7)	0.7 (0.7.0.7)	0.8 (0.7.0.9)	0.10	0.8 (0.7.1.0)	0.44	0.76				
All symptoms	0.7 (0.7, 0.7)	0.7 (0.7, 0.7)	0.8 (0.7, 0.8)	0·19	0.8 (0.7, 1.0)		0· /6 0·46				
Upper respiratory	1.0 (1.0, 1.0)	1.0 (1.0, 1.0)	1.0 (0.9, 1.1) 0.9 (0.8, 1.0)	0.52	1.0 (0.8, 1.4)	0.58					
Lower respiratory	0.8 (0.8, 0.8)	0.8 (0.8, 0.8)		0.23	1.0 (0.8, 1.2)	0.12	0.37				
Systemic	0.5 (0.5, 0.6)	0.5 (0.5, 0.6)	0.6 (0.5, 0.7)	0.08	0.6 (0.4, 0.8)	0.78	0.72				

¹ Influenza-like illness (ILI) is defined as an acute onset of measured fever of ≥37·8°C plus cough.
2 Use of antipyretics was only asked from participants who reported a symptom of fever/feverish, those who did not have fever were assumed to have not taken any antipyretics.

190 191 192	3 Compared between influenza virus PCR test-positive versus test-negative regardless of RSV PCR test results. p-value ≤0·05 is highlighted in bold.
192	4 Compared between RSV PCR test-positive versus test-negative regardless of influenza virus PCR test results, p-value <0.05 is highlighted

- 4 Compared between RSV PCR test-positive versus test-negative regardless of influenza virus PCR test results. p-value ≤0.05 is highlighted in bold.

 5 Compared between influenza virus PCR test-positive versus RSV PCR test-positive. p-value ≤0.05 is highlighted in bold.

 6 All the information excepted measured body temperature ≥37.8°C have <5% unknown status, with unknown status assumed to be absent.

Appendix Table 9. Self-reported symptom severity score among acute respiratory illness (ARI) episodes presenting the specific symptom.

		Acut	e respiratory illness (AR	I) episodes	
	All ARI	ARI with PCR negative for both influenza and RSV	PCR-confirmed influenza ARI	PCR-confirmed RSV ARI	PCR- confirm ed influenz a vs. RSV ARI
	(N=822)	(N=705)	(N=93)	(N=20)	
	n ¹ Mean (%) (95% CI)	n ¹ Mean (%) (95% CI)	n ¹ Mean p- (%) (95% CI) value 2	$n^1 (\%) \frac{\text{Mean (95\%}}{\text{CI)}} \frac{\text{p-}}{\text{value}^3}$	p-value ⁴
Symptom severity score					
Sore throat	500 1·3 (1·2, (61) 1·3)	430 1·3 (1·2, (61) 1·3)	55 1·2 (1·1, (59) 1·3) 0·46	15 (75) $\begin{array}{cc} 1 \cdot 1 & (1 \cdot 0, \\ 1 \cdot 4) \end{array}$ 0.58	0.80
Runny nose or nasal congestion	737 1·4 (1·3, (90) 1·4)	635 1·4 (1·3, (90) 1·4)	80 1·4 (1·3, (86) 1·6) 0·56	18 (90) $\frac{1.4 (1.2, 0.81)}{1.7}$ 0.81	0.99
Cough	786 1·5 (1·4, (96) 1·5)	677 1·4 (1·4, (96) 1·5)	89 1·6 (1·4, (96) 1·7) 0·21	$ \begin{array}{ccc} 20 & 1.8 & (1.5, \\ (100) & 2.1) & 0.10 \end{array} $	0.27
Worsened shortness of breath	138 1·2 (1·1, (17) 1·3)	$117 1 \cdot 2 \ (1 \cdot 1, \\ (17) 1 \cdot 2)$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$4(20) \frac{1 \cdot 0(1 \cdot 0,}{1 \cdot 0)} \leq 0.001$	0.03
Feverishness	367 1·2 (1·2, (45) 1·3)	306 1·2 (1·1, (43) 1·2)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$6(30)$ $\begin{array}{cc} 1.3(1.0, \\ 1.7) \end{array}$ 0.84	0.90
Chills	317 $1 \cdot 2 (1 \cdot 1, (39) 1 \cdot 2)$	266 1·2 (1·1, (38) 1·2)	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	7 (35) $\frac{1.1 (1.0, 0.97)}{1.4}$	0.93
Myalgia (Body or muscle aches and pain)	289 1·2 (1·1, (35) 1·2)	241 1·2 (1·1, (34) 1·2)	$\begin{array}{cccc} 37 & 1.2 & (1.1, \\ (40) & 1.4) & 0.39 \end{array}$	11 (55) $\frac{1 \cdot 2}{1 \cdot 5}$ $(1 \cdot 0, 0.59)$	0.94
Headache	499 1·2 (1·2, (61) 1·2)	427 1·2 (1·2, (61) 1·2)	55 1·2 (1·1, (59) 1·3) 0·95	$14 (70)$ $\begin{array}{cc} 1 \cdot 3 (1 \cdot 0, \\ 1 \cdot 6) \end{array}$ $0 \cdot 80$	0.82

¹ n represented number of participants who had the symptom and reported symptom severity score for that specific symptom. 2 Compared between influenza virus PCR test-positive versus test-negative regardless of RSV PCR test results. p-value ≤ 0.05 is highlighted in bold.

In bold.

3 Compared between RSV PCR test-positive versus test-negative regardless of influenza virus PCR test results. p-value ≤0·05 is highlighted in bold.

⁴ Compared between influenza virus PCR test-positive versus RSV PCR test-positive. p-value ≤0.05 is highlighted in bold.

206


210

Appendix Table 10. Self-reported medical care sought for PCR-confirmed influenza or RSV ARIs.


	Age (years)							
		60 - 69		70 - 79		80 - 89		Overall
	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)	n	% (95% CI)
All ARI (N=8	322), p-	value = 0⋅36						
Hospitalized	5	1.6% (0.3, 3.1)	8	2.6% (1.0, 4.6)	9	4.5% (2.0, 7.6)	22	2.7% (1.6, 3.8)
Ambulatory	210	65.4% (60.4,	190	62.7% (57.1,	127	64.1% (57.1,	528	64.1% (60.8,
care only		70.4)		68.0)		70.7)		67.3)
Did not seek	105	32.7% (27.7,	103	34.0% (28.7,	62	31.3% (24.7,	272	32.8% (29.7,
medical		37.7)		39.6)		37.9)		36.0)
attention								
T. Cl.	ı nev	DCD A DI	(NI 705)	0.02				
		PCR-negative ARI			0	5 20/ (2 2 0 4)	17	2 40/ (1 2 2 7)
Hospitalized	2	0.7% (0, 1.8)	6	2.3% (0.8, 4.3)	9	5.3% (2.3, 9.4)	17	2.4% (1.3, 3.7)
Ambulatory	176	63.5% (57.4,	156	60.7% (54.9,	112	65.5% (58.5,	445	63.0% (59.4,
care only	00	69.0)	0.5	66.5)	50	71.9)	246	66.7)
Did not seek	99	35.7% (30.0,	95	37.0% (31.1,	50	29.2% (22.8,	246	34.6% (30.9,
medical		41.5)		43.2)		35.7)		38.0)
attention								
PCR-confirm	ed infl	uenza ARI (N=93),	p-value	= 0.05				
Hospitalized	3	8.6% (0, 17.2)	1	2.7% (0, 8.1)	0	0% (0, 3.2)	4	4.3% (1.1, 8.6)
Ambulatory	29	82.9% (71.4,	30	81.1% (67.6,	13	61.9% (42.9,	72	77.4% (68.8,
care only		94.3)		91.9)		81.0)		86.0)
Did not seek	3	8.6% (0, 20.0)	6	16.2% (5.4,	8	38.1% (19.0,	17	18.3% (10.8,
medical				29.7)		57.1)		26.9)
attention								
PCR-confirm	ed RS	V ARI (N=20) , p-va	due = 0.7	74				
Hospitalized	0	0% (0, 15·0)	1	14.3% (0, 42.9)	0	0% (0, 15.0)	1	5.0% (0, 15.0)
Ambulatory	5	71.4% (42.9,	3	42.9% (14.3,	3	50.0% (16.7,	11	55.0% (35.0,
care only	Ü	100)		85.7)		83.3)		75.0)
Did not seek	2	28.6% (0, 57.1)	2	28.6% (0, 71.4)	3	50.0% (16.7,	7	35.0% (15.0,
medical	-	(0,0,1)	_	(0, 1, 1)	Ü	83.3)	•	55.0)
attention						/		/

Note: There were statistically significant differences between age groups and medical care sought, among those with influenza and RSV-negative ARIs (p-value = 0·03), and among those with PCR-confirmed influenza ARIs (p-value = 0·05). Unlike in Table 4, here the categorization to "hospitalized", "ambulatory care only" and "did not seek medical attention" was mutually exclusive.


Appendix Figures




Appendix Figure 1. 2015 population percentage by five-year age groups and gender for (A) China, (B) Jiangsu Province, (C) Suzhou and (D) Yancheng.





Appendix Figure 2. (A) Incidence of PCR-confirmed influenza acute respiratory illness (ARI) and RSV ARI per 10,000 person-weeks. (B) Weekly numbers of PCR-confirmed influenza ARI by influenza A virus subtypes or influenza B virus lineages. Number of influenza isolates in the past four weeks in (C) Jiangsu Province and (D) China as reported by Chinese Center for Disease Control and Prevention in Influenza Weekly Report.




Appendix Figure 3. Cumulative incidences of (A) PCR-confirmed influenza ARI, (B) PCR-confirmed RSV ARI, (C) medically attended influenza ARI, (D) medically attended RSV ARI, (E) influenza-associated hospitalization, and (F) RSV-associated hospitalization, by study year and age group. Blue: 60–69 years old; Red: 70–79 years old; Orange: 80–89 years old; Black: All-ages and weighed with Jiangsu province population age and sex structure.













Appendix Figure 4. Self-rated symptom severity for each symptom during ARI episodes among (A) all ARI, (B) influenza and RSV PCR-negative ARI, (C) PCR-confirmed influenza ARI and (D) PCR-confirmed RSV ARI. Red: Severe; Orange: Moderate; Yellow: Mild; Grey: Not present.









Appendix Figure 5. Medical care utilization for ARI episodes by age group, among (A) all ARIs, (B) ARIs that were PCR-test negative for both influenza virus and RSV, (C) PCR-confirmed influenza ARIs and (D) PCR-confirmed RSV ARIs. Dark blue: Participant was hospitalized; Light blue: Participant sought ambulatory care only (and was not hospitalized); Cyan: Participant did not seek medical attention.

References

242

- 243 1. Yu H, Alonso WJ, Feng L, et al. Characterization of regional influenza seasonality
- 244 patterns in China and implications for vaccination strategies: spatio-temporal modeling of
- 245 surveillance data. *PLoS Med* 2013; **10**(11): e1001552.
- 246 2. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory Syncytial
- Virus Seasonality: A Global Overview. J Infect Dis 2018; 217(9): 1356-64.
- Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden
- and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study.
- 250 Lancet Respir Med 2014; **2**(6): 445-54.
- 251 4. VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of
- symptom severity in adults with influenza and other acute respiratory illness in the outpatient
- 253 setting. *BMC Infect Dis* 2014; **14**: 231.
- 5. Wu C, Gong Y, Wu J, et al. Chinese Version of the EQ-5D Preference Weights:
- 255 Applicability in a Chinese General Population. *PLoS One* 2016; **11**(10): e0164334.
- Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive
- 257 'vital signs' measure for dementia screening in multi-lingual elderly. *Int J Geriatr Psychiatry* 258 2000; **15**(11): 1021-7.
- 259 7. Cowling BJ, Xu C, Tang F, et al. Cohort profile: the China Ageing REespiratory
- infections Study (CARES), a prospective cohort study in older adults in Eastern China. *BMJ Open* 2017; **7**(10): e017503.
- 8. Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure
- for creating a frailty index. BMC Geriatr 2008; 8: 24.
- Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
- 265 data capture (REDCap)--a metadata-driven methodology and workflow process for providing
- translational research informatics support. J Biomed Inform 2009; **42**(2): 377-81.
- 267 10. Fowler KB, Gupta V, Sullender W, et al. Incidence of symptomatic A(H1N1)pdm09
- influenza during the pandemic and post-pandemic periods in a rural Indian community. Int J
- 269 *Infect Dis* 2013; **17**(12): e1182-5.
- 270 11. Tinoco YO, Azziz-Baumgartner E, Uyeki TM, et al. Burden of Influenza in 4
- 271 Ecologically Distinct Regions of Peru: Household Active Surveillance of a Community
- 272 Cohort, 2009-2015. Clin Infect Dis 2017; **65**(9): 1532-41.
- 273 12. National Notifiable Diseases Surveillance System (NNDSS). Downloads and
- 274 Resources: MMWR Weeks Calendars. 2018. https://wwwn.cdc.gov/nndss/downloads.html
- 275 (accessed October 18, 2016 2016).
- 276 13. Fowlkes A, Steffens A, Temte J, et al. Incidence of medically attended influenza
- during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance
- 278 Project, 2009-13. Lancet Respir Med 2015; **3**(9): 709-18.
- 279 14. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right?
- 280 Interpreting zero numerators. *JAMA* 1983; **249**(13): 1743-5.
- 281 15. Cowling BJ, Chan KH, Fang VJ, et al. Comparative epidemiology of pandemic and
- seasonal influenza A in households. *N Engl J Med* 2010; **362**(23): 2175-84.
- 283 16. University of California. Global Administrative Areas. 2019. https://gadm.org/
- 284 (accessed October 21 2019).

285